ArticleVeterinary research2025
Recombinant pseudorabies virus expressing the consensus VP2 protein of porcine parvovirus 1 (PPV1) protects pigs against pseudorabies virus and PPV1.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing the Major Neutralizing Epitopes A and D of Transmissible Gastroenteritis Virus Spike Protein.Veterinary sciences · 2026Article
- Advances in the application of recombinant herpesvirus-vectored vaccines in animal disease control.Frontiers in microbiology · 2026Review
- PRV gD-Based DNA Vaccine Candidates Adjuvanted with cGAS, UniSTING, or IFN-α Enhance Protective Immunity.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pseudorabies virus (PRV) and porcine parvovirus type 1 (PPV1) are major pathogens that cause reproductive disorders in sows, and mixed infections are frequently detected on pig farms. In this study, a recombinant PRV (rPRV-VP2) based on a PRV variant (HLJ8) was constructed to express the PPV1 VP2 protein. To ensure safety, four virulence genes (TK, gE, gI, and UL39) of PRV HLJ8 were deleted, followed by further evaluation of safety and immunogenicity in piglets. The PPV1 VP2 expression cassette was inserted into the gE/gI deletion site, enabling successful expression of the VP2 protein, which exhibited hemagglutination activity with a titre of 1:64. Animal experiments demonstrated that rPRV-VP2 elicited robust antibody responses against both PRV and PPV1, providing complete protection in both mice and piglets. Compared with commercial PRV and PPV1 vaccines, rPRV-VP2 conferred comparable or superior protection, resulting in not only no clinical symptoms but also significantly reduced viral loads in tissues. The deletion of the gE gene can distinguish wild-type virus infection from vaccine immunity in clinical applications. Overall, rPRV-VP2 offers a safe and effective strategy for dual protection against PRV and PPV1, reducing vaccination costs in pig production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.